Accessibility Menu
Cyclerion Therapeutics logo

Cyclerion Therapeutics(NASDAQ) CYCN

Market Cap$16.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2019)-99%
5 Year-95%
1 Year+26%
1 Month+2%
$3.55
+1.43%
+0.05Today
Cyclerion Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 3.512026-08-04
Cyclerion Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.29%USD 3.502026-07-28
1 month+2.33%USD 3.432026-07-02
3 month+8.33%USD 3.242026-05-06
Year to date+176.38%USD 1.272025-12-31
1 year+25.97%USD 2.792025-08-04
3 year+5.41%USD 3.332023-08-04
5 year-94.55%USD 64.402021-08-05
Since inception-98.6%USD 250.002019-03-18

Cyclerion Therapeutics Financials at a Glance

Market Cap

$16.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$1.90M

Net Income (TTM)

-$4.95M

EPS (TTM)

-$1.37

P/E Ratio

-2.56

Dividend

$0.00

Beta (Volatility)

0.93 (Low)

Price

$3.55

Volume

31,214

Open

$3.49

Previous Close

$3.51

Daily Range

$3.43 - $3.67

52-Week Range

$1.03 - $8.48

Estimated Earnings Date

Aug 4, 2026

CYCN News

Beaten

Why Cyclerion Therapeutics Is Crashing Today

George Budwell, PhDOct 14, 2020
Shares down

Here’s Why Cyclerion Therapeutics Stock Plummeted Today

Brian Orelli, PhDOct 30, 2019

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Cyclerion Therapeutics

Cyclerion develops medicines for people with serious brain and nervous system diseases. Its main focus is on new treatments for depression that does not respond to standard drugs. The company also earns income by licensing older drug candidates to other firms.

What’s in the Cyclerion Medicine Cabinet?

  • Treatment-Resistant Depression Therapy: New therapy in development for people whose depression does not improve with standard treatments. (0% of revenue in Q2 2025; not yet commercialized)
  • Praliciguat: Drug candidate for high blood pressure and kidney disease, licensed to Akebia Therapeutics. (100% of Q2 2025 revenue from olinciguat option agreement)
  • Olinciguat: Drug candidate for sickle cell disease, with a license option held by a third party. (Revenue from option/license agreements in Q2 2025)
  • Legacy Legacy CNS Drug Assets: Includes zagociguat and CY3018, now sold to Tisento Therapeutics for further development in rare brain disorders. (No direct revenue in Q2 2025)

Growth and Expansion: The Cyclerion Timeline

  • 2019: Spun off from Ironwood Pharmaceuticals and listed on Nasdaq.
  • 2023-2025: Sold and licensed legacy drug assets to Akebia Therapeutics and Tisento Therapeutics.
  • 2025: Shifted focus to new depression therapy; raised $1.375 million in private placement.
  • 2025: Established at-the-market equity program to raise up to $20 million.

What Makes Cyclerion Stand Out?

Cyclerion operates with a single employee and relies on consultants, keeping costs low. The company generates revenue by licensing or selling its drug candidates to other firms. Its current focus is on developing a new therapy for hard-to-treat depression, while monetizing older assets.

Five Things You Need to Know

  • Revenue was $93,000 in Q2 2025, up from $0 in Q2 2024.
  • Net loss improved to $324,000 in Q2 2025, a 75.5% reduction year-over-year.
  • Cash and cash equivalents were $3.0 million as of June 30, 2025.
  • Research and development expenses fell 47% year-over-year in Q2 2025.
  • Company expects current cash to last into Q1 2026.

Bottom Line

Cyclerion has shifted from developing its own drugs to licensing and selling assets. The company now focuses on new depression treatments while managing costs and seeking new funding.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1

CEO

Regina Graul, PhD

Website

www.cyclerion.com

Headquarters

Cambridge, MA 02142, US

CYCN Financials

Key Financial Metrics (TTM)

Gross Margin

61.58%

Operating Margin

-359.16%

Net Income Margin

-260.63%

Return on Equity

-64.94%

Return on Capital

-54.74%

Return on Assets

-71.46%

Earnings Yield

-39.06%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.68M

Volume

31.21K

Avg. Volume

33.87K

Financials (TTM)

Gross Profit

$1.17M

Operating Income

-$6.82M

EBITDA

-$6.72M

Operating Cash Flow

-$4.45M

Capital Expenditure

-$66.00K

Free Cash Flow

-$4.52M

Cash & ST Invst.

$1.39M

Total Debt

$0.00

Cyclerion Therapeutics Performance Analysis

Cyclerion Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 297,000-92.5%
20232023-12-31USD 0N/A
20242024-12-31USD 2,000,000N/A
20252025-12-31USD 2,074,0003.7%
Cyclerion Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30840.9%
Q42025-12-3117.1%
Q12026-03-31-100.0%
Q22026-06-30N/A
Cyclerion Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -20.28-23.1%
20232023-12-31USD -8.99-55.7%
20242024-12-31USD -1.21-86.5%
20252025-12-31USD -1.11-8.6%
Cyclerion Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-172.7%
Q42025-12-3116.7%
Q12026-03-31-204.0%
Q22026-06-3046.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$16.43MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$16.43M

N/A

Employees

1

N/A

Net Income

$0.00

+100.0%

EBITDA

-$1.77M

-446.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$1.39M

-53.7%

Total Debt

$0.00

N/A

Accounts Receivable

$0.00

-100.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-71.46%

N/A

Return on Invested Capital

-1.34%

N/A

Free Cash Flow

-$1.43M

-184.7%

Operating Cash Flow

-$1.43M

-184.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
VYNEVYNE Therapeutics Inc.
$28.56+0.00%
PLRZPolyrizon Ltd.
$10.20-3.68%
QNRXQuoin Pharmaceuticals, Ltd.
$4.35-2.25%
XTLBXTL Biopharmaceuticals Ltd.
$2.88+0.67%

Trending Stocks

Symbol / CompanyPricePrice Chg
EAElectronic Arts
$209.70-0.00%
SPCXSpace Exploration Technologies
$125.33+0.09%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$37.26-0.10%
TQQQProShares Trust - ProShares UltraPro Qqq
$74.82+0.10%

Questions About CYCN

What is the current price of Cyclerion Therapeutics?

Cyclerion Therapeutics is trading at $3.51 per share.

What is the 52-week range for Cyclerion Therapeutics?

Over the past 52 weeks, Cyclerion Therapeutics has traded between $1.03 and $8.48.

How much debt does Cyclerion Therapeutics have?

As of the most recent reporting period, Cyclerion Therapeutics reported total debt of $0.00.

How much cash does Cyclerion Therapeutics have on hand?

Cyclerion Therapeutics reported $2.82M in cash and cash equivalents in its most recent financial results.

What is Cyclerion Therapeutics’s dividend yield?

Cyclerion Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services